Key Figures
(as of 30 September 2022)
| Staff | 145 |
| Products in development | 14 |
| Partnered products | 5 |
| Clinical readouts in 2022 | 7 |
| Clinical study initiations in 2022 | 3 |
| Cash for operations | CHF 140.5 million |
| Fully financed until | Q3 2024 |
| Debt | None |
| Shares outstanding | 83.6 million |
| Total funds raised from investors | CHF 353.6 million |
| Total funds received from partnering | CHF 337.9 million |
| Potential total milestones from partners | CHF 3.3 billion |